Cinzia Baldessari

First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status

Francesco Facchinetti, Giulia Mazzaschi, Fausto Barbieri et al. · European Journal of Cancer · 2020 · 147 citations · Full text

Medicine, Oncology, Pharmacology +13

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

Alessio Cortellini, Marcello Tiseo, Giuseppe Luigi Banna et al. · Cancer Immunology Immunotherapy · 2020 · 93 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)

Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna et al. · Therapeutic Advances in Medical Oncology · 2021 · 93 citations · Full text

Medicine, Immunology, Oncology +17

Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression ≥ 50% and Their Relationship With Clinical Outcomes

Alessio Cortellini, Alex Friedlaender, Giuseppe Luigi Banna et al. · Clinical Lung Cancer · 2020 · 84 citations · Full text

Pharmacy, Immunology, Pharmacotherapy +16

Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort

Giuseppe Fornarini, Sara Elena Rebuzzi, Giuseppe Luigi Banna et al. · ESMO Open · 2021 · 56 citations · Full text

Medicine, Immunology, Oncology +17